Britain and America have agreed to a landmark commercial pact that will ensure no levies on UK pharmaceutical shipments going into the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on pharmaceuticals through the public health system. This move guarantees that tariffs on these crucial exports will stay at zero for a period of the next three years.
This deal comes after previous threats to significantly raise tariffs on branded drug products, with increases discussed up to double the cost.
"This agreement with the UK bolsters the global environment for innovative medicines and brings much-needed fairness to U.S.–U.K. pharmaceutical trade," a statement said.
Trade Importance
Drugs represent one of the UK's most significant export categories to the United States, which is easily the biggest buyer for leading companies like GSK and AstraZeneca.
Export figures show that in the one-year period leading up to September, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This figure represented a significant portion of total UK exports in that period.
"This guarantee secures jobs, boosts investment and facilitates the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary commented.
Detailed NHS Changes
The agreement entails several key commitments from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to double overall public funding on treatments from 0.3% of the national economy to 0.6 percent over the next decade.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to control costs will be limited at fifteen percent. In the past, rebates exceeded 20%.
Broader Context
The deal follows a ongoing row between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
The disagreement were exacerbated by claims that US consumers were paying a premium for the equivalent treatments than people in the UK and Europe.
Recently, several large drug company projects in the UK have been halted or abandoned, while major investments have been directed toward US facilities.
A senior figure acknowledged that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a share of its overall budget over the previous ten-year period.
